In Vitro Tear Replenishment System: Assessing Drug Delivery from Contact Lens Biomaterials Through Corneal Epithelial Monolayer and Multilayer Under Replenishment Conditions

Overview

Journal Drug Deliv Transl Res

Publisher Springer

Specialty Pharmacology

Date 2024 Dec 5

PMID 39636534

Authors

Saman Mohammadi

Shahabedin Eslami

Lyndon Jones

Maud Gorbet

Affiliations

Soon will be listed here.

Abstract

There is a need to develop improved in vitro ocular models for biocompatibility and drug delivery studies to assess the potential of in vivo performance of contact lenses. By using an in vitro corneal epithelial cell model combined with a tear replenishment method, this study aimed to investigate the delivery of the glaucoma drug latanoprost from contact lenses and compare the dynamic release results to no-replenishment (immersion) conditions. Corneal epithelial cells were grown as a monolayer or multilayer on curved cellulose cell culture inserts. Three contact lens materials (balafilcon A; senofilcon A; etafilcon A), soaked for 24 h in latanoprost, were placed on the curved cornea models (CCM) and drug concentration was determined on the basal (diffusion/transport) and apical (supernatant) sides after 1, 4, 8 and 12 h. The in vitro tear replenishment was achieved via intermittent flow of a tear solution over the CCM at a rate of 1 mL/hour. A zero-order kinetic was observed for basal drug concentration over the 12 h period. Similar basal and apical drug concentrations were observed with monolayer and multilayer CCM, except for the etafilcon A material. The apical release of latanoprost was significantly lower under replenishment compared to no-replenishment conditions. These results demonstrate the role that a dynamic release model will have in predicting the amount of drug that can be released from a contact lens into the tear film and the critical role of a cell monolayer in in vitro drug delivery studies.

References

Pereira-da-Mota A, Phan C, Concheiro A, Jones L, Alvarez-Lorenzo C . Testing drug release from medicated contact lenses: The missing link to predict in vivo performance. J Control Release. 2022; 343:672-702. DOI: 10.1016/j.jconrel.2022.02.014. View

Jones L, Hui A, Phan C, Read M, Azar D, Buch J . CLEAR - Contact lens technologies of the future. Cont Lens Anterior Eye. 2021; 44(2):398-430. DOI: 10.1016/j.clae.2021.02.007. View

Rykowska I, Nowak I, Nowak R . Soft Contact Lenses as Drug Delivery Systems: A Review. Molecules. 2021; 26(18). PMC: 8472272. DOI: 10.3390/molecules26185577. View

Sjoquist B, Stjernschantz J . Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002; 47 Suppl 1:S6-12. DOI: 10.1016/s0039-6257(02)00302-8. View

York M, Steiling W . A critical review of the assessment of eye irritation potential using the Draize rabbit eye test. J Appl Toxicol. 1998; 18(4):233-40. DOI: 10.1002/(sici)1099-1263(199807/08)18:4<233::aid-jat496>3.0.co;2-y. View

Debbasch C, Ebenhahn C, Dami N, Pericoi M, Berghe C, Cottin M . Eye irritation of low-irritant cosmetic formulations: correlation of in vitro results with clinical data and product composition. Food Chem Toxicol. 2004; 43(1):155-65. DOI: 10.1016/j.fct.2004.09.004. View

Castro-Munozledo F . Corneal epithelial cell cultures as a tool for research, drug screening and testing. Exp Eye Res. 2008; 86(3):459-69. DOI: 10.1016/j.exer.2007.11.017. View

Musther H, Olivares-Morales A, Hatley O, Liu B, Hodjegan A . Animal versus human oral drug bioavailability: do they correlate?. Eur J Pharm Sci. 2013; 57:280-91. PMC: 4107270. DOI: 10.1016/j.ejps.2013.08.018. View

Reichl S, Kolln C, Hahne M, Verstraelen J . In vitro cell culture models to study the corneal drug absorption. Expert Opin Drug Metab Toxicol. 2011; 7(5):559-78. DOI: 10.1517/17425255.2011.562195. View

10.

Postnikoff C, Pintwala R, Williams S, Wright A, Hileeto D, Gorbet M . Development of a curved, stratified, in vitro model to assess ocular biocompatibility. PLoS One. 2014; 9(5):e96448. PMC: 4023926. DOI: 10.1371/journal.pone.0096448. View

11.

Griffith M, Osborne R, Munger R, Xiong X, Doillon C, Laycock N . Functional human corneal equivalents constructed from cell lines. Science. 1999; 286(5447):2169-72. DOI: 10.1126/science.286.5447.2169. View

12.

Hornof M, Toropainen E, Urtti A . Cell culture models of the ocular barriers. Eur J Pharm Biopharm. 2005; 60(2):207-25. DOI: 10.1016/j.ejpb.2005.01.009. View

13.

Reichl S, Bednarz J, Muller-Goymann C . Human corneal equivalent as cell culture model for in vitro drug permeation studies. Br J Ophthalmol. 2004; 88(4):560-5. PMC: 1772077. DOI: 10.1136/bjo.2003.028225. View

14.

Xiang C, Batugo M, Gale D, Zhang T, Ye J, Li C . Characterization of human corneal epithelial cell model as a surrogate for corneal permeability assessment: metabolism and transport. Drug Metab Dispos. 2009; 37(5):992-8. DOI: 10.1124/dmd.108.026286. View

15.

Chang J, Basu S, Lee V . Air-interface condition promotes the formation of tight corneal epithelial cell layers for drug transport studies. Pharm Res. 2000; 17(6):670-6. DOI: 10.1023/a:1007569929765. View

16.

Subrizi A, Del Amo E, Korzhikov-Vlakh V, Tennikova T, Ruponen M, Urtti A . Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties. Drug Discov Today. 2019; 24(8):1446-1457. DOI: 10.1016/j.drudis.2019.02.001. View

17.

Zhang T, Xiang C, Gale D, Carreiro S, Wu E, Zhang E . Drug transporter and cytochrome P450 mRNA expression in human ocular barriers: implications for ocular drug disposition. Drug Metab Dispos. 2008; 36(7):1300-7. DOI: 10.1124/dmd.108.021121. View

18.

Mannermaa E, Vellonen K, Urtti A . Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev. 2006; 58(11):1136-63. DOI: 10.1016/j.addr.2006.07.024. View

19.

Duvvuri S, Majumdar S, Mitra A . Role of metabolism in ocular drug delivery. Curr Drug Metab. 2004; 5(6):507-15. DOI: 10.2174/1389200043335342. View

20.

Vellonen K, Hellinen L, Mannermaa E, Ruponen M, Urtti A, Kidron H . Expression, activity and pharmacokinetic impact of ocular transporters. Adv Drug Deliv Rev. 2017; 126:3-22. DOI: 10.1016/j.addr.2017.12.009. View